<strong>Co</strong>ncerns•y The <strong>in</strong>struments were validated for use <strong>in</strong> a general health survey context,<strong>and</strong> it is unclear to what extent it may be useful <strong>in</strong> o<strong>the</strong>r populations.However, prelim<strong>in</strong>ary studies <strong>in</strong>dicate that this measure is useful <strong>in</strong>crim<strong>in</strong>al justice sett<strong>in</strong>gs (Swartz & Lurigio, 2005)Availability <strong>and</strong> <strong>Co</strong>stThe K6 <strong>and</strong> K10 scales are available at no charge at http://www.hcp.med.harvard.edu/ncs/ftpdir/k6/K6+self%20adm<strong>in</strong>-3-05-%20FINAL.pdf. Information regard<strong>in</strong>gscor<strong>in</strong>g, cut<strong>of</strong>f scores, <strong>and</strong> validation research are available at http://www.hcp.med.harvard.edu/ncs/k6_scales.php.The Mental Health <strong>Screen<strong>in</strong>g</strong> Form-III (MHSF-III)The MHSF-III was designed as an <strong>in</strong>itial psychological screen<strong>in</strong>g for use withclients enter<strong>in</strong>g substance abuse treatment programs. The 18-item measureconta<strong>in</strong>s yes/no questions exam<strong>in</strong><strong>in</strong>g current <strong>and</strong> past mental health symptoms.Positive responses <strong>in</strong>dicate <strong>the</strong> possibility <strong>of</strong> a current problem <strong>and</strong> should befollowed up by questions regard<strong>in</strong>g <strong>the</strong> duration, <strong>in</strong>tensity, <strong>and</strong> co-occurrence <strong>of</strong>symptoms. The follow<strong>in</strong>g disorders are addressed <strong>in</strong> <strong>the</strong> MHSF-III: schizophrenia,depressive disorders, posttraumatic stress disorder (PTSD), phobias, <strong>in</strong>termittentexplosive disorder, delusional disorder, sexual <strong>and</strong> gender identity disorders,eat<strong>in</strong>g disorders, manic episode, panic disorder, obsessive-compulsive disorder,pathological gambl<strong>in</strong>g, learn<strong>in</strong>g disorders, <strong>and</strong> mental retardation. The preferredmode <strong>of</strong> adm<strong>in</strong>istration is via <strong>in</strong>terview, although <strong>the</strong> <strong>in</strong>strument can also beself-adm<strong>in</strong>istered. A qualified mental health pr<strong>of</strong>essional should review responsesto determ<strong>in</strong>e whe<strong>the</strong>r a follow-up assessment <strong>and</strong>/or diagnostic workup <strong>and</strong>treatment recommendations are needed.Positive Features•y Prelim<strong>in</strong>ary research with <strong>the</strong> MHSF-III <strong>in</strong>dicate that it has excellentcontent validity <strong>and</strong> adequate test-retest reliability <strong>and</strong> construct validity(Carroll & McG<strong>in</strong>ley, 2001)•y The <strong>in</strong>strument is quite brief to adm<strong>in</strong>ister, requir<strong>in</strong>g approximately 15m<strong>in</strong>utes•y The <strong>in</strong>strument was designed to use with <strong>in</strong>dividuals who have co-occurr<strong>in</strong>gsubstance abuse problems•y English <strong>and</strong> Spanish versions <strong>of</strong> <strong>the</strong> MHSF-III are available<strong>Co</strong>ncerns•y The reliability <strong>and</strong> validity studies were conducted <strong>in</strong> a s<strong>in</strong>gle agency <strong>and</strong>with only a modest sample size•y S<strong>in</strong>ce <strong>the</strong> MHSF-III cont<strong>in</strong>ues to undergo test<strong>in</strong>g <strong>and</strong> validation, <strong>the</strong>re isonly a moderate amount <strong>of</strong> published research on this <strong>in</strong>strument67
•yThe <strong>in</strong>strument has not been used extensively <strong>in</strong> crim<strong>in</strong>al justicepopulationsAvailability <strong>and</strong> <strong>Co</strong>stThe MHSF-III is available to download at no cost at http://www.asapnys.org/Resources/mhscreen.pdf, <strong>and</strong> from <strong>the</strong> Alcoholism <strong>and</strong> Substance Abuse Providers<strong>of</strong> New York State at http://www.asapnys.org/resources.html.Symptom Checklist 90–Revised (SCL-90-R)The SCL-90-R is an updated version <strong>of</strong> <strong>the</strong> Hopk<strong>in</strong>s Symptom Checklist(Derogatis, Lipman, & Rickels, 1974) <strong>and</strong> <strong>the</strong> SCL-90. The <strong>in</strong>strument providesa 90-item, multidimensional self-report <strong>in</strong>ventory that is designed to assessphysical <strong>and</strong> psychological distress dur<strong>in</strong>g <strong>the</strong> previous week. The <strong>in</strong>strumentexam<strong>in</strong>es n<strong>in</strong>e major dimensions <strong>of</strong> psychopathology, <strong>in</strong>clud<strong>in</strong>g somatization,obsessive compulsiveness, <strong>in</strong>terpersonal sensitivity, depression, anxiety, hostility,phobic anxiety, paranoid ideation, <strong>and</strong> psychoticism. The Global Severity Indexfor <strong>the</strong> SCL-90-R can be used to provide a summary score <strong>of</strong> psychopathology.The SCL-90-R is available <strong>in</strong> three formats: paper <strong>and</strong> pencil, audiocassette, <strong>and</strong>computerized adm<strong>in</strong>istration. The BSI is an abbreviated version (53 items) <strong>of</strong> <strong>the</strong>SCL-90-R <strong>and</strong> is somewhat easier to score.Positive Features•y The <strong>in</strong>strument requires no tra<strong>in</strong><strong>in</strong>g <strong>and</strong> is brief to adm<strong>in</strong>ister•y The <strong>in</strong>strument has been frequently used <strong>in</strong> crim<strong>in</strong>al justice sett<strong>in</strong>gs <strong>and</strong>has been found to outperform o<strong>the</strong>r general measures <strong>of</strong> psychologicalfunction<strong>in</strong>g among substance abus<strong>in</strong>g populations (Davidson & Taylor,2001; Franken & Hendriks, 2001)•y Internal consistency <strong>of</strong> <strong>the</strong> SCL-90 is good, based on results from <strong>the</strong>normative sample, with Cronbach’s alpha on <strong>the</strong> n<strong>in</strong>e subscales rang<strong>in</strong>gfrom .77–.90 (Derogatis, Melisaratos, Rickles, & Rock, 1976)•y When used as a screener for psychiatric disorders <strong>in</strong> nonpsychiatricpopulations us<strong>in</strong>g a criteria <strong>of</strong> a t-score greater than 63, sensitivity <strong>and</strong>specificity range from .73–.88 <strong>and</strong> .80–.92 respectively (Peveler & Fairburn,1990)<strong>Co</strong>ncerns•y The SCL-90 has poor specificity (39%) <strong>in</strong> diagnos<strong>in</strong>g depression amongalcoholics (94%; Rounsaville et al., 1979)•y An exam<strong>in</strong>ation <strong>of</strong> <strong>the</strong> factor structure <strong>of</strong> <strong>the</strong> SCL-90-R <strong>in</strong> substanceabus<strong>in</strong>g populations suggests a s<strong>in</strong>gle factor <strong>of</strong> general psychopathology,<strong>in</strong>dicat<strong>in</strong>g that <strong>the</strong> SCL-90-R fails to differentiate among mental disorders<strong>in</strong> <strong>the</strong>se sett<strong>in</strong>gs (Zack, Toneatto, & Stre<strong>in</strong>er, 1998)68
- Page 1:
Screening and Assessmentof Co-Occur
- Page 5 and 6:
Screening Instruments for Co-Occurr
- Page 12 and 13:
daunting task, and often requires t
- Page 14 and 15:
Importance of Screening and Assessm
- Page 16 and 17:
•y•y•y•y•y•y•y•y•
- Page 18 and 19:
Developing a Comprehensive Screenin
- Page 20 and 21:
•y•y•y•y•y•y•y•y•
- Page 22 and 23:
These areas of cognitive and behavi
- Page 24 and 25:
•y•y•y•y•y•y•y•yAlc
- Page 26 and 27: frequency of drug testing may be ta
- Page 28 and 29: offer expanded tests that also incl
- Page 30 and 31: self-disclosure of mental health or
- Page 32 and 33: should be determined by the severit
- Page 34 and 35: Special Clinical Issues in Screenin
- Page 36: suicide screening is important for
- Page 39 and 40: Maintaininga staff ofdiverse ethnic
- Page 41 and 42: The MHSF-III and the GAIN-SS were f
- Page 43 and 44: Key Information to Include in Asses
- Page 45 and 46: •y•y`` Vocational and education
- Page 47 and 48: approximately two hours. Either the
- Page 49 and 50: Texas Christian University Drug Scr
- Page 51 and 52: & Cirimele, 2006). Hair testing can
- Page 53 and 54: Appendix B: Screening Instruments f
- Page 55 and 56: Suicide Probability Scale (SPS)The
- Page 57 and 58: Positive Features•y•y•yThe TS
- Page 59 and 60: Appendix D: Screening Instruments f
- Page 61 and 62: Positive Features•y•y•y•yTh
- Page 63 and 64: Positive Features•y•y•y•y
- Page 65 and 66: Appendix F: Screening Instruments T
- Page 67 and 68: Availability and CostThe CAMH-CDS i
- Page 69 and 70: and one Axis II disorder (antisocia
- Page 71 and 72: Appendix G: Screening Instruments f
- Page 73 and 74: prior hospitalization for mental he
- Page 75: •yThe instrument has been used wi
- Page 79 and 80: Appendix H: Screening Instruments f
- Page 81 and 82: Positive Features•y•y•y•y
- Page 83 and 84: have you felt you ought to Cut down
- Page 85 and 86: Concerns•y•y•yThe DALI was de
- Page 87 and 88: •y•y•y•y•y•y•ywith sc
- Page 89 and 90: Concerns80•y•y•y•y•y•y
- Page 91 and 92: Concerns•y The validity of the SS
- Page 93 and 94: Appendix I: Recommended Instruments
- Page 95 and 96: Concerns•y•y•y•yReliabiliti
- Page 97 and 98: •y•y•y•yScales and profile
- Page 99 and 100: •y•yand non-interpretable resul
- Page 101 and 102: Appendix L: Assessment Instruments
- Page 103 and 104: Philadelphia, PA 19106, (215) 399-0
- Page 105 and 106: treatment setting. Treatment progra
- Page 107 and 108: Concerns•y•y•yThe CIDI is qui
- Page 109 and 110: •y•y•yThe PDSQ has been used
- Page 111 and 112: Both a Research Version and a Clini
- Page 113 and 114: 104
- Page 115 and 116: Bastiaens, L., Riccardi, K., & Sakh
- Page 117 and 118: Carey, K. B., Carey, M. P., & Chand
- Page 119 and 120: Demmel, R., Beck, B., Richter, D.,
- Page 121 and 122: Gray, B. T. (2001). A factor analyt
- Page 123 and 124: Kessler, R. C., Wittchen, H. U., Ab
- Page 125 and 126: McLellan, A. T., Cacciola, J. S., &
- Page 127 and 128:
Nochajski, T. H., & Stasiewicz, P.
- Page 129 and 130:
Rollnick, H., Heather, N., Gold, R.
- Page 131 and 132:
Teitelbaum L. M., & Mullen, B. (200
- Page 133:
Zimmerman, M., & Sheeran, T. (2003)